Terms: = Lung cancer AND SPOP, TEF2, 8405, ENSG00000121067, O43791 AND Treatment
5 results:
1. Genomic Features of lung-Recurrent Hormone-Sensitive Prostate cancer.
Fonseca NM; Van der Eecken K; Herberts C; Verbeke S; Ng SWS; Lumen N; Ritch E; Murtha AJ; Bernales CQ; Schönlau E; Moris L; Van Dorpe J; Annala M; Wyatt AW; Ost P
JCO Precis Oncol; 2022 Apr; 6():e2100543. PubMed ID: 35507889
[TBL] [Abstract] [Full Text] [Related]
2. Influencing factors of depressive symptoms in patients with malignant tumour.
Wang D; He N; Liu Y; Pang R; Dilixiati M; Wumaier A
J Int Med Res; 2021 Dec; 49(12):3000605211062450. PubMed ID: 34894827
[TBL] [Abstract] [Full Text] [Related]
3. The emerging role of spop protein in tumorigenesis and cancer therapy.
Song Y; Xu Y; Pan C; Yan L; Wang ZW; Zhu X
Mol Cancer; 2020 Jan; 19(1):2. PubMed ID: 31901237
[TBL] [Abstract] [Full Text] [Related]
4. spop promotes FADD degradation and inhibits NF-κB activity in non-small cell lung cancer.
Luo J; Chen B; Gao CX; Xie HK; Han CN; Zhou CC
Biochem Biophys Res Commun; 2018 Sep; 504(1):289-294. PubMed ID: 30190126
[TBL] [Abstract] [Full Text] [Related]
5. spop promotes SIRT2 degradation and suppresses non-small cell lung cancer cell growth.
Luo J; Bao YC; Ji XX; Chen B; Deng QF; Zhou SW
Biochem Biophys Res Commun; 2017 Feb; 483(2):880-884. PubMed ID: 28073696
[TBL] [Abstract] [Full Text] [Related]
